leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...8485868788899091929394...235236»
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal, Real-world evidence:  Simulating Colorectal Cancer Trials Using Real-World Data. (Pubmed Central) -  Jul 23, 2022   
    Evaluation of alternative chemotherapy regimens in patients with SMAD4 alterations will be important to distinguish whether this represents a prognostic or predictive biomarker. In this study, we simulated five CRC trials, and tested two simulation scenarios with several different configurations demonstrated that our simulations can robustly generate effectiveness and safety outcomes comparable with the original trials using real-world data.
  • ||||||||||  numidargistat (INCB001158) / Calithera
    Trial primary completion date, Combination therapy, Metastases:  A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors (clinicaltrials.gov) -  Jul 21, 2022   
    P1/2,  N=149, Active, not recruiting, 
    In this study, we simulated five CRC trials, and tested two simulation scenarios with several different configurations demonstrated that our simulations can robustly generate effectiveness and safety outcomes comparable with the original trials using real-world data. Trial primary completion date: Jun 2022 --> Dec 2022
  • ||||||||||  5-fluorouracil / Generic mfg.
    A CASE OF UNRESECTABLE LOCALLY ADVANCED PANCREATIC CANCER SUCCESSFULLY RESECTED BY COMBINING CHEMOTHERAPY AND HIFU THERAPY (Science Lounge) -  Jul 20, 2022 - Abstract #UEGW2022UEGW_2750;    
    There was no indication for surgery, and then chemotherapy (modified FOLFIRINOX; mFFX) was enforced due to unresectable locally advanced PC (Stage III)...Therefore, HIFU was re-performed on the soft tissue at the resection site, and the patient is currently under observation. In conclusion, the combination of chemo and HIFU therapy may be promising therapies for patients with unresectable locally advanced PC for achieving curative resection.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    A CHALLENGING CASE OF LYNCH SYNDROME AND THE FEASIBILITY OF ENDOSCOPIC SUBMUCOSAL DISSECTION IN LESIONS INVOLVING SURGICAL ANASTOMOSIS (Science Lounge) -  Jul 20, 2022 - Abstract #UEGW2022UEGW_2716;    
    Even though an extensive colectomy is the recommended treatment for this syndrome, it does not eliminate the risk of rectal cancer, being essential its frequent endoscopic surveillance. In addition, a lesion superimposed in a previous surgical anastomosis entails technical difficulties to endoscopic submucosal dissection by the presence of severe fibrosis and staples, however the technique seems possible, safe and preferential when compared to surgery.
  • ||||||||||  PREDICTORS OF MAJOR PATHOLOGICAL RESPONSE AFTER NEOADJUVANT THERAPY FOR BORDERLINE AND LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA (Lehar 2) -  Jul 20, 2022 - Abstract #UEGW2022UEGW_1583;    
    FOLFIRINOX was administered in 78 (39.0%) patients, gemcitabine+nab-paclitaxel in 54(27.0%) patients, gemcitabine+oxaliplatin in 33(16.5%), and 6(3.0%) underwent other regimens... Patients who experienced a major pathologic response have a favourable prognosis, and major pathologic response is confirmed as an independent predictor of increased OS. A normal CA19-9 and radiological tumor residual size after neoadjuvant treatment were confirmed to be independent predictors of major pathologic response.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    TUMORAL STATUS OF ATM DETERMINES CANCER-ASSOCIATED FIBROBLAST CELL FATE IN PANCREATIC DUCTAL ADENOCARCINOMA (Lehar 4) -  Jul 20, 2022 - Abstract #UEGW2022UEGW_1409;    
     Overall, our data validate the concept of a specific tumor-stroma dialog depending on the mutational status of tumor cells which leads to the emergence of a distinct tumor microenvironment, actively participating in supporting pancreatic tumorigenesis. Finally, our study highlights the interest in identifying tumor and stromal subtypes to develop combinatorial and personalized chemotherapeutic regimens to redirect stromal differentiation and support tumor cell eradication.
  • ||||||||||  Trial primary completion date:  Mature B-Cell Lymphoma And Leukemia Study III (clinicaltrials.gov) -  Jul 20, 2022   
    P2/3,  N=168, Recruiting, 
    Trial primary completion date: May 2024 --> Oct 2024 Trial primary completion date: Oct 2022 --> Nov 2023
  • ||||||||||  Trial completion date, Trial primary completion date, Metastases:  FOLFOXIRI With or Without Intensification for Rectal Cancer (clinicaltrials.gov) -  Jul 20, 2022   
    P2,  N=72, Recruiting, 
    Trial primary completion date: Oct 2022 --> Nov 2023 Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2022 --> Mar 2023
  • ||||||||||  ompenaclid (RGX-202) / Inspirna, EMD Serono
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  RGX-202-001: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer (clinicaltrials.gov) -  Jul 20, 2022   
    P1,  N=60, Recruiting, 
    Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2022 --> Mar 2023 Trial completion date: May 2022 --> Dec 2023 | Trial primary completion date: Dec 2021 --> May 2023
  • ||||||||||  New P2 trial:  TRIPP-FFX: FOLFIRINOX Versus OncoSil (clinicaltrials.gov) -  Jul 20, 2022   
    P2,  N=80, Not yet recruiting, 
  • ||||||||||  aclarubicin / Generic mfg.
    Journal:  The identification of the anthracycline aclarubicin as an effective cytotoxic agent for pancreatic cancer. (Pubmed Central) -  Jul 17, 2022   
    Proliferation and colony formation assays were performed to determine the anticancer activity of anthracyclines; aclarubicin and doxorubicin, on commercial and patient-derived, low-passage PDAC cell lines...Aclarubicin showed superior antitumor activity compared to other anthracyclines and standard of care drugs (gemcitabine and individual components of FOLFIRINOX) in a patient-derived, low-passage PDAC cell line and in commercial cell lines...Aclarubicin is cytotoxic for commercial and patient-derived low-passage PDAC cell lines, at doses lower than peak serum concentrations for patient treatment. Our findings support a (re)consideration of aclarubicin as a backbone of new combination regimens for pancreatic cancer patients.
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
    Review, Journal:  Liposomal irinotecan (Onivyde™): Exemplifying the benefits of nanotherapeutic drugs. (Pubmed Central) -  Jul 16, 2022   
    nal-IRI exemplifies how liposomal encapsulation of a chemotherapeutic agent can alter its PK properties, improving clinical outcomes for patients. nal-IRI is currently under investigation in other malignancies including biliary tract cancer (amongst other gastrointestinal cancers), brain tumors and small-cell lung cancer.